Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 428 articles:
HTML format
Text format



Single Articles


    September 2019
  1. RESNICK MJ
    Re: Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
    J Urol. 2019 Sep 13:101097JU0000000000000550. doi: 10.1097/JU.0000000000000550.
    PubMed     Text format    


  2. ATALA A
    Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis.
    J Urol. 2019 Sep 12:10109701JU0000585156807772.
    PubMed     Text format    


  3. WEINSTOCK C, Suzman D, Kluetz P, Baxley J, et al
    Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop.
    J Urol. 2019 Sep 10:101097JU0000000000000532. doi: 10.1097/JU.0000000000000532.
    PubMed     Text format     Abstract available


  4. VAN KALMTHOUT LWM, van Melick HHE, Lavalaye J, Meijer RP, et al
    Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
    J Urol. 2019 Sep 5:101097JU0000000000000531. doi: 10.1097/JU.0000000000000531.
    PubMed     Text format     Abstract available


  5. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Tian Z, et al
    Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.
    J Urol. 2019 Sep 4:101097JU0000000000000527. doi: 10.1097/JU.0000000000000527.
    PubMed     Text format     Abstract available


  6. PAK S, Park SY, Shin TJ, You D, et al
    Reply by Authors.
    J Urol. 2019;202:531-532.
    PubMed     Text format    


  7. O'NEILL M, Alibhai SMH
    Editorial Comment.
    J Urol. 2019;202:530-531.
    PubMed     Text format    


  8. KARAKIEWICZ PI
    Editorial Comment.
    J Urol. 2019;202:531.
    PubMed     Text format    


  9. GORE JL
    Editorial Comment.
    J Urol. 2019;202:524.
    PubMed     Text format    


  10. STOYANOVA R
    Editorial Comment.
    J Urol. 2019;202:505.
    PubMed     Text format    


  11. NAYAN M, Fleshner N, Bozzo A
    Editorial Comment.
    J Urol. 2019;202:504-505.
    PubMed     Text format    


  12. PISANSKY TM, Thompson IM, Valicenti RK, D'Amico AV, et al
    Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
    J Urol. 2019;202:533-538.
    PubMed     Text format     Abstract available


  13. VECCIA A, Antonelli A, Francavilla S, Porpiglia F, et al
    Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies.
    J Urol. 2019;202:511-517.
    PubMed     Text format     Abstract available


  14. BALAKRISHNAN AS, Cowan JE, Cooperberg MR, Shinohara K, et al
    Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    J Urol. 2019;202:506-510.
    PubMed     Text format     Abstract available


    August 2019
  15. TOURINHO-BARBOSA RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, et al
    Focal Therapy for Localized Prostate Cancer with Either HIFU or Cryoablation: A Single Institution Experience.
    J Urol. 2019 Aug 22:101097JU0000000000000506. doi: 10.1097/JU.0000000000000506.
    PubMed     Text format     Abstract available


  16. DAMBAL S, Howard LE, Allott EH, Aronson WJ, et al
    Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration-Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494.
    PubMed     Text format     Abstract available


  17. ITO K, Yokomizo A, Tokunaga S, Arai G, et al
    Diagnostic Impacts of Clinical Laboratory-Based [-2] proPSA Indices on Any Grade, Gleason Grade Group >/=2 or >/=3 of Prostate Cancer in the PSA Below 10 ng/mL.
    J Urol. 2019 Aug 20:101097JU0000000000000495. doi: 10.1097/JU.0000000000000495.
    PubMed     Text format     Abstract available


  18. BAHLER CD, Green M, Hutchins GD, Cheng L, et al
    PSMA-Targeted Positron Emission Tomography (PET) in Evaluation of Patients with Primary Prostate Cancer: Comparison of Pre-operative [(68)Ga]Ga-PSMA-11 PET/CT, Immediate Post-operative Specimen [(68)Ga]Ga-PSMA-11 Imaging, and Whole Mount Pathology.
    J Urol. 2019 Aug 20:101097JU0000000000000501. doi: 10.1097/JU.0000000000000501.
    PubMed     Text format     Abstract available


  19. MAGANTY A, Sabik LM, Sun Z, Eom KY, et al
    Undertreatment of Prostate Cancer in Rural Residents.
    J Urol. 2019 Aug 20:101097JU0000000000000500. doi: 10.1097/JU.0000000000000500.
    PubMed     Text format     Abstract available


  20. TANEJA SS
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000058011614376.
    PubMed     Text format    


  21. KAPLAN SA
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798646485082.
    PubMed     Text format    


  22. TANEJA SS
    Re: Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000057984426332.
    PubMed     Text format    


  23. TANEJA SS
    Re: Recovery of Pad-Free Continence in Elderly Men Does Not Differ from Younger Men Undergoing Robot-Assisted Radical Prostatectomy for Aggressive Prostate Cancer.
    J Urol. 2019 Aug 12:101097JU0000000000000491. doi: 10.1097/JU.0000000000000491.
    PubMed     Text format    


  24. KAPLAN SA
    Re: Oxidative Damage in Patients with Benign Prostatic Hyperplasia and Prostate Cancer Co-Exposed to Phthalates and to Trace Elements.
    J Urol. 2019 Aug 12:10109701JU000057986087720.
    PubMed     Text format    


  25. RESNICK MJ
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798568009731.
    PubMed     Text format    


  26. XU L, Mao X, Grey A, Scandura G, et al
    Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
    J Urol. 2019 Aug 7:101097JU0000000000000475. doi: 10.1097/JU.0000000000000475.
    PubMed     Text format     Abstract available


  27. DAL MORO F, Pizzolito S
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000474. doi: 10.1097/JU.0000000000000474.
    PubMed     Text format    


  28. BUCKLEY RJ
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000473. doi: 10.1097/JU.0000000000000473.
    PubMed     Text format    


  29. SUNDI D, Nyame YA
    Editorial Comment.
    J Urol. 2019;202:254-255.
    PubMed     Text format    


  30. MOUL JW
    Editorial Comment.
    J Urol. 2019;202:254.
    PubMed     Text format    


  31. LUIS DE CASTRO ABREU A, Jadvar H
    Editorial Comment.
    J Urol. 2019;202:420-421.
    PubMed     Text format    


  32. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    Reply by Authors.
    J Urol. 2019;202:271.
    PubMed     Text format    


  33. PORTER CR
    Editorial Comment.
    J Urol. 2019;202:270.
    PubMed     Text format    


  34. SANCHEZ-SALAS R, Stabile A
    Editorial Comment.
    J Urol. 2019;202:270-271.
    PubMed     Text format    


  35. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:263.
    PubMed     Text format    


  36. SIEGEL C
    Re: Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.
    J Urol. 2019;202:190.
    PubMed     Text format    


    July 2019
  37. ATALA A
    Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 31:10109701JU000057944436265.
    PubMed     Text format    


  38. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.
    J Urol. 2019 Jul 30:101097JU0000000000000471. doi: 10.1097/JU.0000000000000471.
    PubMed     Text format     Abstract available


  39. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Hemi-Gland Cryoablation for Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 years.
    J Urol. 2019 Jul 26:101097JU0000000000000456. doi: 10.1097/JU.0000000000000456.
    PubMed     Text format     Abstract available


  40. TANEJA SS
    Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2019 Jul 11:10109701JU0000577260122781.
    PubMed     Text format    


  41. TANEJA SS
    Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 11:101097JU0000000000000443. doi: 10.1097/JU.0000000000000443.
    PubMed     Text format    


  42. ATALA A
    Re: The Proteogenomic Landscape of Curable Prostate Cancer.
    J Urol. 2019 Jul 9:10109701JU000057698013730.
    PubMed     Text format    


  43. SIEGEL C
    Re: PTEN Expression in Prostate Cancer: Relationship with Clinicopathologic Features and Multiparametric MRI Findings.
    J Urol. 2019 Jul 8:101097JU0000000000000428. doi: 10.1097/JU.0000000000000428.
    PubMed     Text format    


  44. WALTON-DIAZ A, Madariaga-Venegas M
    Editorial Comment.
    J Urol. 2019;202:106-107.
    PubMed     Text format    


  45. FRASER M
    Editorial Comment.
    J Urol. 2019;202:95.
    PubMed     Text format    


  46. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:101.
    PubMed     Text format    


  47. BRAVI CA, Tin A, Vertosick E, Mazzone E, et al
    The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.
    J Urol. 2019;202:108-113.
    PubMed     Text format     Abstract available


    June 2019
  48. HANSON HA, Martin C, O'Neil B, Leiser CL, et al
    The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
    J Urol. 2019 Jun 27:101097JU0000000000000416. doi: 10.1097/JU.0000000000000416.
    PubMed     Text format     Abstract available


  49. MANNAERTS CK, Wildeboer RR, Remmers S, van Kollenburg RAA, et al
    Multiparametric ultrasound for prostate cancer detection and localization: Correlation of B-mode, shearwave elastography and contrast-enhanced ultrasound with radical prostatectomy specimens.
    J Urol. 2019 Jun 27:101097JU0000000000000415. doi: 10.1097/JU.0000000000000415.
    PubMed     Text format     Abstract available


  50. FAROLFI A, Gafita A, Calais J, Eiber M, et al
    (68)Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
    J Urol. 2019 Jun 24:101097JU0000000000000417. doi: 10.1097/JU.0000000000000417.
    PubMed     Text format     Abstract available


  51. TANEJA SS
    Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsies.
    J Urol. 2019 Jun 24:10109701JU000056971634429.
    PubMed     Text format    


  52. RESNICK MJ
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU000057441601701.
    PubMed     Text format    


  53. TANEJA SS
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU00005749769074752.
    PubMed     Text format    


  54. FRIEDLANDER TW, Welty C, Anantharaman A, Schonhoft JD, et al
    Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.
    J Urol. 2019 Jun 19:101097JU0000000000000393. doi: 10.1097/JU.0000000000000393.
    PubMed     Text format     Abstract available


  55. LAVIANA AA, Hernandez A, Huang LC, Zhao Z, et al
    Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes?
    J Urol. 2019 Jun 19:101097JU0000000000000392. doi: 10.1097/JU.0000000000000392.
    PubMed     Text format     Abstract available


  56. MARGEL D, Peer A, Ber Y, Shavit-Grievink L, et al
    Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease.
    J Urol. 2019 Jun 12:101097JU0000000000000384. doi: 10.1097/JU.0000000000000384.
    PubMed     Text format     Abstract available


  57. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000379. doi: 10.1097/JU.0000000000000379.
    PubMed     Text format    


  58. SIEGEL C
    Re: A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
    J Urol. 2019 Jun 5:101097JU0000000000000371. doi: 10.1097/JU.0000000000000371.
    PubMed     Text format    


  59. SHAH N, Ioffe V
    Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Keyan Salari et al. JOU. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000362. doi: 10.1097/JU.0000000000000362.
    PubMed     Text format    


  60. SALARI K, Feldman AS
    Re: Salari et al. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. JUrol. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363.
    PubMed     Text format    


  61. FERNANDO H, Garcia C, Hossack T, Ahmadi N, et al
    Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy: A Systematic Review.
    J Urol. 2019;201:1072-1079.
    PubMed     Text format     Abstract available


  62. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:1126.
    PubMed     Text format    


  63. AYDIN AM, Pow-Sang JM
    Editorial Comment.
    J Urol. 2019;201:1125-1126.
    PubMed     Text format    


  64. CROOK J
    Editorial Comment.
    J Urol. 2019;201:1133.
    PubMed     Text format    


  65. THOMPSON JE, Sridhar AN, Tan WS, Freeman A, et al
    Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
    J Urol. 2019;201:1134-1143.
    PubMed     Text format     Abstract available


    May 2019
  66. HANNA N, Wszolek MF, Mojtahed A, Nicaise E, et al
    MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER.
    J Urol. 2019 May 30:101097JU0000000000000359. doi: 10.1097/JU.0000000000000359.
    PubMed     Text format     Abstract available


  67. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357.
    PubMed     Text format     Abstract available


  68. MURALIDHAR V, Mahal BA, Butler S, Lamba N, et al
    Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer.
    J Urol. 2019 May 30:101097JU0000000000000352. doi: 10.1097/JU.0000000000000352.
    PubMed     Text format     Abstract available


  69. GULATI R, Psutka SP, Etzioni R
    Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication.
    J Urol. 2019 May 21:101097JU0000000000000346. doi: 10.1097/JU.0000000000000346.
    PubMed     Text format     Abstract available


  70. SHARMA V, Wymer KM, Borah BJ, Barocas DA, et al
    Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    J Urol. 2019 May 21:101097JU0000000000000345. doi: 10.1097/JU.0000000000000345.
    PubMed     Text format     Abstract available


  71. ZUNIGA KB, Zhao S, Kenfield SA, Cedars B, et al
    Trends in complementary and alternative medicine use among patients with prostate cancer.
    J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336.
    PubMed     Text format     Abstract available


  72. GRIEBLING TL
    Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures.
    J Urol. 2019 May 10:10109701JU000055973645783.
    PubMed     Text format    


  73. GONTERO P, Marra G, Alessio P, Filippini C, et al
    Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.
    J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327.
    PubMed     Text format     Abstract available


  74. TANEJA SS
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    J Urol. 2019 May 7:101097JU0000000000000323. doi: 10.1097/JU.0000000000000323.
    PubMed     Text format    


  75. TANEJA SS
    Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    J Urol. 2019 May 7:10109701JU0000559603179075.
    PubMed     Text format    


  76. ATALA A
    Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
    J Urol. 2019 May 7:101097JU0000000000000330. doi: 10.1097/JU.0000000000000330.
    PubMed     Text format    


  77. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 May 7:10109701JU0000559616036260.
    PubMed     Text format    


  78. TOM MC, Nguyen JK, Luciano R, Mian OY, et al
    Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    J Urol. 2019 May 6:101097JU0000000000000316. doi: 10.1097/JU.0000000000000316.
    PubMed     Text format     Abstract available


  79. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Text format     Abstract available


  80. CARTER HB
    Editorial Comment.
    J Urol. 2019;201:922.
    PubMed     Text format    


  81. DALL'ERA M
    Editorial Comment.
    J Urol. 2019;201:935-936.
    PubMed     Text format    


  82. MOORE C
    Editorial Comment.
    J Urol. 2019;201:928.
    PubMed     Text format    


  83. SRIVASTAVA A, Joshi SS
    Editorial Comment.
    J Urol. 2019;201:949.
    PubMed     Text format    


  84. FAISAL FA, Tosoian JJ, Han M, Macura KJ, et al
    Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
    J Urol. 2019;201:937-942.
    PubMed     Text format     Abstract available


    April 2019
  85. HAESE A, Trooskens G, Steyaert S, Hessels D, et al
    Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
    J Urol. 2019 Apr 26:101097JU0000000000000293. doi: 10.1097/JU.0000000000000293.
    PubMed     Text format     Abstract available


  86. JOHNSON DC, Kwok E, Ahn C, Pashchinskiy A, et al
    Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model.
    J Urol. 2019 Apr 22:101097JU0000000000000283. doi: 10.1097/JU.0000000000000283.
    PubMed     Text format     Abstract available


  87. DASKIVICH TJ, Thomas IC, Luu M, Shelton JB, et al
    External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Apr 22:101097JU0000000000000287. doi: 10.1097/JU.0000000000000287.
    PubMed     Text format     Abstract available


  88. TANEJA SS
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial.
    J Urol. 2019 Apr 8:10109701JU00005577560832916.
    PubMed     Text format    


  89. TANEJA SS
    Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Urol. 2019 Apr 8:101097JU0000000000000276. doi: 10.1097/JU.0000000000000276.
    PubMed     Text format    


  90. TEWARI AK, Taouli B
    Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness.
    J Urol. 2019 Apr 8:101097JU0000000000000272. doi: 10.1097/JU.0000000000000272.
    PubMed     Text format     Abstract available


  91. CEDARS BE, Washington SL 3rd, Cowan JE, Leapman M, et al
    STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.
    J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.
    PubMed     Text format     Abstract available


  92. SHOAG J, Liu D, Ma X, Oromendia C, et al
    MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  93. SANDHU HS, Mulholland DJ
    MP68-11 IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  94. VELLKY J, Ricke W
    MP68-13 DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  95. FAISAL F, Alshalalfa M, Davicioni E, Karnes RJ, et al
    MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  96. JAMASPISHVILI T, Patel P, Niu Y, Vidotto T, et al
    MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  97. ADSHEAD J, Oldfield F, Hadaschik B, Wouter Everaerts JA, et al
    MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  98. RICHIE JP
    Re: Association between Vasectomy and Risk of Testicular Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:667-668.
    PubMed     Text format    


  99. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed     Text format    


  100. HARPER BT, Dykes TE, Terris MK
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    


  101. SAMMON J
    Editorial Comment.
    J Urol. 2019;201:733-734.
    PubMed     Text format    


  102. GRUBB R
    Editorial Comment.
    J Urol. 2019;201:740-741.
    PubMed     Text format    


  103. KEEGAN KA
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    


  104. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:733.
    PubMed     Text format    


  105. CARROLL P, Schmidt B
    Editorial Comment.
    J Urol. 2019;201:820.
    PubMed     Text format    


  106. MARTIN C, Haaland B, Tward AE, Dechet C, et al
    Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.
    J Urol. 2019;201:751-758.
    PubMed     Text format     Abstract available


    March 2019
  107. ATALA A
    Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth.
    J Urol. 2019 Mar 29:101097JU0000000000000251. doi: 10.1097/JU.0000000000000251.
    PubMed     Text format    


  108. RESNICK MJ
    Re: Risk of Prostate Cancer in Men Treated with 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Urol. 2019 Mar 29:10109701JU00005577312536940.
    PubMed     Text format    


  109. ATALA A
    Re: Targeting FOXA1-Mediated Repression of TGF-beta Signaling Suppresses Castration-Resistant Prostate Cancer Progression.
    J Urol. 2019 Mar 29:10109701JU000055773048240.
    PubMed     Text format    


  110. PAK S, Park SY, Shin TJ, You D, et al
    Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer.
    J Urol. 2019 Mar 27:101097JU0000000000000249. doi: 10.1097/JU.0000000000000249.
    PubMed     Text format     Abstract available


  111. TANEJA SS
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    J Urol. 2019 Mar 13:101097JU0000000000000231. doi: 10.1097/JU.0000000000000231.
    PubMed     Text format    


  112. AMINSHARIFI A, Simon R, Polascik TJ, Robertson CN, et al
    Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.
    J Urol. 2019 Mar 5:101097JU0000000000000207. doi: 10.1097/JU.0000000000000207.
    PubMed     Text format     Abstract available


  113. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    The ratio of the number of biopsy specimens to prostate volume (biopsy density) > 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
    J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204.
    PubMed     Text format     Abstract available


  114. WANG CS, Jhan JH, Li CC
    Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Po
    J Urol. 2019;201:627-628.
    PubMed     Text format    


  115. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
    J Urol. 2019;201:528-534.
    PubMed     Text format     Abstract available


  116. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
    J Urol. 2019;201:510-519.
    PubMed     Text format     Abstract available


  117. MIRAK SA, Shakeri S, Bajgiran AM, Felker ER, et al
    Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS version 2 Category and Staging with Whole Mount Histopathology Correlation.
    J Urol. 2019;201:496-502.
    PubMed     Text format     Abstract available


  118. LI-SHENG CHEN S, Ching-Yuan Fann J, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
    J Urol. 2019;201:486-495.
    PubMed     Text format     Abstract available


  119. ATALA A
    Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions.
    J Urol. 2019;201:447.
    PubMed     Text format    


  120. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:446-447.
    PubMed     Text format    


  121. TANEJA SS
    Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    J Urol. 2019;201:443-444.
    PubMed     Text format    


  122. TANEJA SS
    Re: Association between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer.
    J Urol. 2019;201:443.
    PubMed     Text format    


  123. HELFAND BT
    Editorial Comment.
    J Urol. 2019;201:494.
    PubMed     Text format    


  124. EPSTEIN J
    Editorial Comment.
    J Urol. 2019;201:540.
    PubMed     Text format    


  125. MORASH C
    Editorial Comment.
    J Urol. 2019;201:527.
    PubMed     Text format    


  126. ABDI H, Breau RH
    Editorial Comment.
    J Urol. 2019;201:518.
    PubMed     Text format    


  127. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:509.
    PubMed     Text format    


    February 2019
  128. FEI B, Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo O, et al
    Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
    J Urol. 2019 Feb 28:101097JU0000000000000200. doi: 10.1097/JU.0000000000000200.
    PubMed     Text format     Abstract available


  129. TAN N, Bavadian N, Calais J, Oyoyo U, et al
    Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198.
    PubMed     Text format     Abstract available


  130. GREENLAND NY, Zhang L, Cowan JE, Carroll PR, et al
    Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000175. doi: 10.1097/JU.0000000000000175.
    PubMed     Text format     Abstract available


  131. STOVSKY M, Klein EA, Chait A, Manickam K, et al
    Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000185. doi: 10.1097/JU.0000000000000185.
    PubMed     Text format     Abstract available


  132. ECHEVARRIA MI, Awasthi S, Cheng CH, Berglund AE, et al
    African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.
    J Urol. 2019 Feb 15:101097JU0000000000000193. doi: 10.1097/JU.0000000000000193.
    PubMed     Text format     Abstract available


  133. GAFFNEY C, Golan R, Cantu MD, Scognamiglio T, et al
    The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    J Urol. 2019 Feb 12:101097JU0000000000000170. doi: 10.1097/JU.0000000000000170.
    PubMed     Text format     Abstract available


  134. TANEJA SS
    Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000169.
    PubMed     Text format    


  135. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554059.66296.
    PubMed     Text format    


  136. STEFANOVA V, Buckley R, Flax S, Spevack L, et al
    Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability.
    J Urol. 2019 Feb 8:101097JU0000000000000156. doi: 10.1097/JU.0000000000000156.
    PubMed     Text format     Abstract available


  137. DAMODARAN S, Lang JM, Jarrard DF
    Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000117.
    PubMed     Text format     Abstract available


  138. ATALA A
    Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554005.76376.
    PubMed     Text format    


  139. ATALA A
    Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554004.38258.
    PubMed     Text format    


  140. GRIEBLING TL
    Re: Localised Prostate Cancer in Elderly Men Aged 80-89 Years, Findings from a Population-Based Registry.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553998.44096.
    PubMed     Text format    


  141. GRIEBLING TL
    Re: Alzheimer's Disease is Associated with Prostate Cancer: .
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553997.66966.
    PubMed     Text format    


  142. DAS S, Salami SS, Spratt DE, Kaffenberger SD, et al
    Bringing prostate cancer germline genetics into clinical practice.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000137.
    PubMed     Text format     Abstract available


  143. ZELEFSKY MJ, Goldman DA, Reuter V, Kollmeier M, et al
    Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110.
    PubMed     Text format     Abstract available


  144. FALAGARIO UG, Beksac AT, Martini A, Cumarasamy S, et al
    Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
    J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000134.
    PubMed     Text format     Abstract available


  145. ATALA A
    Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis.
    J Urol. 2019;201:230.
    PubMed     Text format    


  146. ATALA A
    Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer.
    J Urol. 2019;201:230.
    PubMed     Text format    


  147. TANEJA SS
    Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    J Urol. 2019;201:228.
    PubMed     Text format    


  148. TANEJA SS
    Re: Histologic Findings Associated with False Positive Multiparametric Magnetic Resonance Imaging Performed for Prostate Cancer Detection.
    J Urol. 2019;201:227-228.
    PubMed     Text format    


  149. SIEGEL C
    Re: Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    J Urol. 2019;201:208.
    PubMed     Text format    


  150. TILKI D
    Editorial Comment.
    J Urol. 2019;201:340.
    PubMed     Text format    


  151. SCARSBROOK A
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    


  152. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    


  153. THOMPSON JE, Stricker PD
    Editorial Comment.
    J Urol. 2019;201:306-307.
    PubMed     Text format    


  154. CARROLL P
    Editorial Comment.
    J Urol. 2019;201:298-299.
    PubMed     Text format    


  155. CHUA MLK
    Editorial Comment.
    J Urol. 2019;201:291.
    PubMed     Text format    


  156. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:290-291.
    PubMed     Text format    


  157. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:277.
    PubMed     Text format    


  158. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:276.
    PubMed     Text format    


  159. MOSES KA
    Editorial Comment.
    J Urol. 2019;201:267.
    PubMed     Text format    


  160. EGGENER S
    Editorial Comment.
    J Urol. 2019;201:266-267.
    PubMed     Text format    


  161. PIERRARD V, Lebdai S, Kleinclauss F, Azzouzi AR, et al
    Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
    J Urol. 2019;201:315-321.
    PubMed     Text format     Abstract available


  162. KIRMIZ S, Qi J, Babitz SK, Linsell S, et al
    Grade Groups Provide Improved Predictions of Pathological and Early Oncologic Outcomes Compared with Gleason Score Risk Groups.
    J Urol. 2019;201:278-283.
    PubMed     Text format     Abstract available


    January 2019
  163. BOTEJUE M, Abbott D, Danella J, Fonshell C, et al
    Utilization of Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    J Urol. 2019 Jan 31. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  164. BURNS JF, Hurwitz LM, Levie KE, Caumont F, et al
    Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000024.
    PubMed     Text format     Abstract available


  165. GINSBURG KB, Arcot R, Qi J, Linsell SM, et al
    Confirmatory MRI With or Without Biopsy Impacts Decision-Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000059.
    PubMed     Text format     Abstract available


  166. GOLD SA, Shih JH, Rais-Bahrami S, Bloom JB, et al
    When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion in Prostate Cancer.
    J Urol. 2019 Jan 23. doi: 10.1097/JU.0000000000000112.
    PubMed     Text format     Abstract available


  167. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samartunga H, et al
    Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Po
    J Urol. 2019 Jan 21. doi: 10.1097/JU.0000000000000053.
    PubMed     Text format     Abstract available


  168. SALARI K, Kuppermann D, Preston MA, Dahl DM, et al
    Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.
    J Urol. 2019 Jan 16. doi: 10.1097/JU.0000000000000031.
    PubMed     Text format     Abstract available


  169. TANEJA SS
    Re: Transcriptomic Heterogeneity in Multifocal Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000101.
    PubMed     Text format    


  170. TANEJA SS
    Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: .
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553310.60445.
    PubMed     Text format    


  171. ATALA A
    Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000096.
    PubMed     Text format    


  172. ZHAO J, Liu J, Sun G, Zhang M, et al
    The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  173. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    J Urol. 2019;201:120-128.
    PubMed     Text format     Abstract available


  174. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
    J Urol. 2019;201:113-119.
    PubMed     Text format     Abstract available


  175. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    J Urol. 2019;201:91-97.
    PubMed     Text format     Abstract available


  176. BLOOM JB, Hale GR, Gold SA, Rayn KN, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    J Urol. 2019;201:84-90.
    PubMed     Text format     Abstract available


  177. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:33-34.
    PubMed     Text format    


  178. ATALA A
    Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics.
    J Urol. 2019;201:33.
    PubMed     Text format    


  179. TANEJA SS
    Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019;201:31.
    PubMed     Text format    


  180. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2019;201:119.
    PubMed     Text format    


  181. STERNBERG IA
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    


  182. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    


  183. GLASER ZA, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2019;201:90.
    PubMed     Text format    


  184. PUNNEN S
    Editorial Comment.
    J Urol. 2019;201:83.
    PubMed     Text format    


  185. PERLIS N
    Editorial Comment.
    J Urol. 2019;201:82.
    PubMed     Text format    


  186. SIVARAMAN A, Kim EH, Andriole GL
    Editorial Comment.
    J Urol. 2019;201:112.
    PubMed     Text format    


    December 2018
  187. FRIEDLANDER DF, von Landenberg N, Loppenberg B, Noldus J, et al
    Facility-Level Variation In Rates Of Definitive Therapy For Low-Risk Prostate Cancer Among Men With Limited Life Expectancy: An Opportunity For Value-Based Care Redesign.
    J Urol. 2018 Dec 24. doi: 10.1097/JU.0000000000000006.
    PubMed     Text format     Abstract available


  188. BEKSAC AT, Cumarasamy S, Falagario U, Xu P, et al
    Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    J Urol. 2018;200:1241-1249.
    PubMed     Text format     Abstract available


    November 2018
  189. KRIMPHOVE MJ, Fletcher SA, Cole AP, Berg S, et al
    Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
    J Urol. 2018 Nov 8. pii: S0022-5347(18)44053-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  190. TANEJA SS
    Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
    J Urol. 2018;200:945-946.
    PubMed     Text format    


  191. TANEJA SS
    Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
    J Urol. 2018;200:945.
    PubMed     Text format    


  192. TANEJA SS
    Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2018;200:944-946.
    PubMed     Text format    


  193. RESNICK MJ
    Re: Quality of Life during Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Urol. 2018;200:936.
    PubMed     Text format    


    October 2018
  194. CHEN SL, Fann JC, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA).
    J Urol. 2018 Oct 23. pii: S0022-5347(18)44024-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  195. ETHERIDGE T, Liou JI, Downs TM, Abel EJ, et al
    The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  196. WALTON E, Yaguchi G, Keeley J, Deebajah M, et al
    Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    J Urol. 2018 Oct 11. pii: S0022-5347(18)43980-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  197. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Urol. 2018 Oct 9. pii: S0022-5347(18)43963-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  198. ITO Y, Udo K, Vertosick EA, Sjoberg DD, et al
    Clinical Utility of Prostate and Tumor Volume-Related Parameters Following Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2018 Oct 6. pii: S0022-5347(18)43967-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  199. ATALA A
    Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.
    J Urol. 2018;200:701-702.
    PubMed     Text format    


  200. TANEJA SS
    Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    J Urol. 2018;200:699.
    PubMed     Text format    


  201. TANEJA SS
    Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial.
    J Urol. 2018;200:698-699.
    PubMed     Text format    


  202. TANEJA SS
    Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    J Urol. 2018;200:697-699.
    PubMed     Text format    


  203. RESNICK MJ
    Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Urol. 2018;200:689.
    PubMed     Text format    


    September 2018
  204. AFSHARI MIRAK S, Shakeri S, Mohammadian Bajgiran A, Felker ER, et al
    3T Multiparametric MRI: Comparison of Performance With and Without Endorectal Coil for Prostate Cancer Detection, PI-RADSv2 Category and Staging with Whole Mount Histopathology Correlation in 429 Patients.
    J Urol. 2018 Sep 28. pii: S0022-5347(18)43960-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  205. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of prostate biopsy with or without pre-biopsy multi-parametric MRI in prostate cancer detection: an observational cohort study.
    J Urol. 2018 Sep 25. pii: S0022-5347(18)43943-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  206. THOMSEN FB, Jakobsen H, Langkilde NC, Borre M, et al
    Active surveillance for localized prostate cancer. Nationwide, observational study.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43911-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  207. LOEB S, Folkvaljon Y, Bratt O, Robinson D, et al
    Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43908-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  208. BALAKRISHNAN AS, Palmer NR, Fergus KB, Gaither TW, et al
    Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): progress and critical areas for improvement.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43872-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  209. RAJARUBENDRA N, Almeida F, Manojlovic Z, Ohe C, et al
    Histologic Validation of (11)Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43871-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  210. OISHI M, Shin T, Ohe C, Nassiri N, et al
    Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
    J Urol. 2018 Sep 3. pii: S0022-5347(18)43794-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  211. KORNBERG Z, Cowan JE, Westphalen AC, Cooperberg MR, et al
    Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43795-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  212. ANDRIOLE GL, Kostakoglu L, Chau A, Duan F, et al
    The Impact of Positron Emission Tomography with (18)F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43798-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  213. GREGG JR, Lopez DS, Reichard C, Zheng J, et al
    Coffee, Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43796-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  214. ATALA A
    Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.
    J Urol. 2018;200:501-502.
    PubMed     Text format    


  215. TANEJA SS
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System.
    J Urol. 2018;200:499.
    PubMed     Text format    


  216. TANEJA SS
    Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Urol. 2018;200:498-499.
    PubMed     Text format    


  217. TANEJA SS
    Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological Features.
    J Urol. 2018;200:497-499.
    PubMed     Text format    


  218. RESNICK MJ
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;200:488-489.
    PubMed     Text format    


  219. BOEHM K
    Editorial Comment.
    J Urol. 2018;200:557.
    PubMed     Text format    


  220. BARR RG
    Editorial Comment.
    J Urol. 2018;200:557-558.
    PubMed     Text format    


  221. MARKS LS
    Editorial Comment.
    J Urol. 2018;200:563.
    PubMed     Text format    


  222. LUDVIGSON A, Sammon J
    Editorial Comment.
    J Urol. 2018;200:581.
    PubMed     Text format    


  223. PINTHUS JH
    Editorial Comment.
    J Urol. 2018;200:580.
    PubMed     Text format    


  224. XU AJ, Taksler GB, Llukani E, Lepor H, et al
    Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.
    J Urol. 2018;200:626-632.
    PubMed     Text format     Abstract available


  225. BABALOLA O, Lee TJ, Viviano CJ
    Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
    J Urol. 2018;200:512-519.
    PubMed     Text format     Abstract available


  226. GUO DP, Thomas IC, Mittakanti HR, Shelton JB, et al
    The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
    J Urol. 2018;200:541-548.
    PubMed     Text format     Abstract available


    August 2018
  227. BERLIN A, Moraes FY, Sanmamed N, Glicksman R, et al
    International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.
    J Urol. 2018 Aug 25. pii: S0022-5347(18)43782-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  228. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.
    J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  229. LOUGHLIN KR
    Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is not Informative.
    J Urol. 2018 Aug 18. pii: S0022-5347(18)43724-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  230. DRUSKIN SC, Mamawala M, Tosoian JJ, Epstein JI, et al
    Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    J Urol. 2018 Aug 13. pii: S0022-5347(18)43703-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  231. LOWRANCE WT, Murad MH, Oh WK, Jarrard DF, et al
    Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
    J Urol. 2018 Aug 4. pii: S0022-5347(18)43671-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  232. CRAWFORD ED, Koo PJ, Shore N, Slovin SF, et al
    A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).
    J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  233. DEAN LW, Assel M, Sjoberg DD, Vickers AJ, et al
    Clinical utility of total length Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer.
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43632-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  234. KEARNS JT, Faino AV, Schenk JM, Newcomb LF, et al
    Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43635-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  235. WINQUIST E
    Editorial Comment.
    J Urol. 2018;200:351-352.
    PubMed     Text format    


  236. SAAD F
    Editorial Comment.
    J Urol. 2018;200:352.
    PubMed     Text format    


  237. STATTIN P
    Editorial Comment.
    J Urol. 2018;200:325-326.
    PubMed     Text format    


  238. LEHRER S
    Editorial Comment.
    J Urol. 2018;200:334.
    PubMed     Text format    


  239. WANG NN, Sonn GA
    Editorial Comment.
    J Urol. 2018;200:318.
    PubMed     Text format    


  240. DOMINGUEZ-ESCRIG JL
    Editorial Comment.
    J Urol. 2018;200:317-318.
    PubMed     Text format    


  241. CRAWFORD ED
    Editorial Comment.
    J Urol. 2018;200:343.
    PubMed     Text format    


  242. JIANG P, Liss MA, Szabo RJ
    Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy.
    J Urol. 2018;200:361-368.
    PubMed     Text format     Abstract available


    July 2018
  243. BLOOM JB, Hale G, Gold SA, Rayn K, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: The Role of a Negative Confirmatory MRI-US Fusion Biopsy.
    J Urol. 2018 Jul 28. pii: S0022-5347(18)43606-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  244. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer-Specific Mortality with Surgery Versus Radiation as Primary Therapy for Localized High-Grade Prostate Cancer in Men Younger than 60 Years Old.
    J Urol. 2018 Jul 27. pii: S0022-5347(18)43599-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  245. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and functional outcome of partial gland ablation with HIFU for localized prostate cancer.
    J Urol. 2018 Jul 20. pii: S0022-5347(18)43550-1. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  246. GOVERS T, Caba L, Resnick MJ
    Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment.
    J Urol. 2018 Jul 13. pii: S0022-5347(18)43530-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  247. TRUONG M
    Editorial Comment.
    J Urol. 2018;200:113.
    PubMed     Text format    


  248. CARLSSON S
    Editorial Comment.
    J Urol. 2018;200:87.
    PubMed     Text format    


  249. RESNICK MJ
    Editorial Comment.
    J Urol. 2018;200:80-81.
    PubMed     Text format    


  250. HUEN KH, Bergman J
    Editorial Comment.
    J Urol. 2018;200:80.
    PubMed     Text format    


  251. ROSENKRANTZ AB, Hemingway J, Hughes DR, Duszak R Jr, et al
    Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population.
    J Urol. 2018;200:89-94.
    PubMed     Text format     Abstract available


  252. GORDETSKY JB, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2018;200:112-113.
    PubMed     Text format    


  253. BHINDI B, Wallis CJD
    Editorial Comment.
    J Urol. 2018;200:125.
    PubMed     Text format    


  254. BAYNE CE
    Re: Missed Opportunities to Decrease Radiation Exposure in Children with Renal Trauma: T. W. Gaither, M. A. Awad, N. V. Leva, G. P. Murphy, B. N. Breyer and H. L. Copp J Urol 2018;199:552-557.
    J Urol. 2018;200:205-206.
    PubMed     Text format    


  255. SCIALPI M, D'Andrea A, Aisa MC, Malaspina CM, et al
    Re: Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: T. Ullrich, M. Quentin, C. Arsov, A. K. Schmaltz, A. Tschischka, N. Laqua, A. Hiester, D. Blondin, R. Rabenalt, P. Albers, G. Antoch and L. Sch
    J Urol. 2018;200:202-204.
    PubMed     Text format    


    June 2018
  256. RICHARDS KA, Liou JI, Cryns VL, Downs TM, et al
    Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  257. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Preisser F, et al
    Anterior localization of prostate cancer suspicious MRI lesions in patients undergoing initial and repeat biopsy: Results from 1,161 patients undergoing MRI/ultrasound fusion-guided targeted biopsies.
    J Urol. 2018 Jun 20. pii: S0022-5347(18)43405-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  258. MARZOUK K, Assel M, Ehdaie B, Vickers A, et al
    Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort.
    J Urol. 2018 Jun 7. pii: S0022-5347(18)43349-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  259. LEPPERT JT, Asch SM, Bergman J
    Ethical Pitfalls When Estimating Life Expectancy For Patients with Prostate Cancer.
    J Urol. 2018 Jun 6. pii: S0022-5347(18)43328-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  260. TANEJA SS
    Re: Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-Effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    J Urol. 2018;199:1397-1398.
    PubMed     Text format    


  261. TANEJA SS
    Re: Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Urol. 2018;199:1396-1398.
    PubMed     Text format    


  262. GRIEBLING TL
    Re: Potential Overtreatment among Men Aged 80 Years and Older with Localized Prostate Cancer in Japan.
    J Urol. 2018;199:1375.
    PubMed     Text format    


  263. GRIEBLING TL
    Re: Safety and Feasibility of Robot-Assisted Radical Prostatectomy for Clinically Localized Prostate Cancer in Elderly Japanese Patients.
    J Urol. 2018;199:1375-1376.
    PubMed     Text format    


  264. GRIEBLING TL
    Re: Long-Term Survival of Patients Aged 80 Years or Older Treated with Radical Prostatectomy for Prostate Cancer.
    J Urol. 2018;199:1374.
    PubMed     Text format    


  265. GRIEBLING TL
    Re: Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    J Urol. 2018;199:1373-1376.
    PubMed     Text format    


  266. GILL IS, Azzouzi AR, Emberton M, Coleman JA, et al
    Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness.
    J Urol. 2018 Jun 1. pii: S0022-5347(18)43299-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    May 2018
  267. RAYN KN, Bloom JB, Gold SA, Hale GR, et al
    Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer.
    J Urol. 2018 May 28. pii: S0022-5347(18)43271-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  268. WEINER AB, Tsai KP, Keeter MK, Victorson DE, et al
    The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.
    J Urol. 2018 May 28. pii: S0022-5347(18)43270-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  269. AMINSHARIFI A, Howard L, Wu Y, De Hoedt A, et al
    Prostate-specific antigen density as a predictor of clinically significant prostate cancer when the PSA level is in the diagnostic "grey-zone": Defining the optimum cut-point stratified by race and body mass index.
    J Urol. 2018 May 11. pii: S0022-5347(18)43126-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  270. HOFBAUER SL, Kittner B, Maxeiner A, Heckmann R, et al
    Validation of PI-RADS version 2 for the detection of prostate cancer.
    J Urol. 2018 May 4. pii: S0022-5347(18)43099-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  271. CRAWFORD ED, Schellhammer PF, McLeod DG, Moul JW, et al
    Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens.
    J Urol. 2018 May 3. pii: S0022-5347(18)43086-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  272. TANEJA SS
    Re: Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-Deficient Prostate Cancer.
    J Urol. 2018;199:1113.
    PubMed     Text format    


  273. TANEJA SS
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;199:1112-1113.
    PubMed     Text format    


  274. SIEGEL C
    Re: Role of MRI in the Use of an Absorbable Hydrogel Spacer in Men Undergoing Radiation Therapy for Prostate Cancer: What the Radiologist Needs to Know.
    J Urol. 2018;199:1092.
    PubMed     Text format    


    April 2018
  275. RAVI P, Karnes RJ, Rangel LJ, Pagliaro LC, et al
    Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    J Urol. 2018 Apr 27. pii: S0022-5347(18)43071-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  276. LARSEN LK, Jakobsen JS, Abdul-Al A, Guldberg P, et al
    Noninvasive detection of high-grade prostate cancer by DNA-methylation analysis of urine cells captured by microfiltration.
    J Urol. 2018 Apr 24. pii: S0022-5347(18)43047-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  277. PATEL HD, Gupta M, Tosoian JJ, Carter HB, et al
    Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  278. GILD P, Cole AP, Krasnova A, Dickerman BA, et al
    Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42984-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  279. RYAN CJ, Crawford ED, Shore ND, Underwood W 3rd, et al
    The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  280. ATALA A
    Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
    J Urol. 2018;199:895-896.
    PubMed     Text format    


  281. TANEJA SS
    Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Urol. 2018;199:893-894.
    PubMed     Text format    


  282. TANEJA SS
    Re: Health-Related Quality of Life for Immediate versus Delayed Androgen-Deprivation Therapy in Patients with Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial.
    J Urol. 2018;199:892-894.
    PubMed     Text format    


  283. CADEDDU JA
    Re: Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for 'Node-Only' Recurrent Prostate Cancer: Technique and Initial Series.
    J Urol. 2018;199:875-876.
    PubMed     Text format    


  284. SIEGEL C
    Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
    J Urol. 2018;199:873.
    PubMed     Text format    


    March 2018
  285. WEI C, Li C, Szewczyk-Bieda M, Upreti D, et al
    Performance characteristics of transrectal shear wave elastography (SWE) imaging in the evaluation of clinically localised prostate cancer: a prospective study.
    J Urol. 2018 Mar 29. pii: S0022-5347(18)42856-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  286. SHAH N, Ioffe V
    Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    J Urol. 2018 Mar 26. pii: S0022-5347(18)42402.
    PubMed     Text format    


  287. PATEL N, Hu JC
    Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    J Urol. 2018 Mar 16. pii: S0022-5347(18)30117-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  288. KLOTZ L, Loblaw A, Siemens R, Ouellette P, et al
    A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon(R)) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for bio
    J Urol. 2018 Mar 10. pii: S0022-5347(18)42502-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  289. RANDALL S, Boyd J, Fuller E, Brooks C, et al
    The effect of vasectomy reversal on prostate cancer risk: International meta-analysis of 684,660 men with vasectomies.
    J Urol. 2018 Mar 7. pii: S0022-5347(18)42489-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  290. PATEL N, Halpern JA, Kasabwala K, Cricco-Lizza E, et al
    Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy.
    J Urol. 2018 Mar 5. pii: S0022-5347(18)42470-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    February 2018
  291. VAN STAM MA, Pieterse AH, van der Poel HG, Bosch JLHR, et al
    Shared Decision-Making in Prostate Cancer Care: Encouraging every patient to be actively involved in decision-making, or ensuring patients' preferred level of involvement?
    J Urol. 2018 Feb 28. pii: S0022-5347(18)42403.
    PubMed     Text format     Abstract available


  292. SAMPURNO F, Zheng J, Di Stefano L, Millar JL, et al
    Quality indicators for global benchmarking of localised prostate cancer management.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39377-7. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  293. MARZOUK S, Naglie G, Tomlinson G, Duff Canning S, et al
    Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39379-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  294. MORTEZAVI A, Marzendorfer O, Donati OF, Rizzi G, et al
    Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
    J Urol. 2018 Feb 20. pii: S0022-5347(18)39373-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  295. BAPAT B
    Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Lobl
    J Urol. 2018 Feb 8. pii: S0022-5347(18)30001-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  296. OZGUR BC
    Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
    J Urol. 2018 Feb 8. pii: S0022-5347(17)78117-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  297. NABHANI JA, Kuang R, Liu H, Kwan L, et al
    Health Changes in Low-income Men Transitioning from a State-funded Prostate Cancer Program to Comprehensive Insurance.
    J Urol. 2018 Feb 6. pii: S0022-5347(18)30183-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  298. ATALA A
    Re: mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer.
    J Urol. 2018;199:344-346.
    PubMed     Text format    


  299. TANEJA SS
    Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    J Urol. 2018;199:342-343.
    PubMed     Text format    


  300. SEFTEL AD
    Re: The Accuracy of Patients' Perceptions of the Risks Associated with Localised Prostate Cancer Treatments.
    J Urol. 2018;199:329.
    PubMed     Text format    


  301. SIEGEL C
    Re: Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience with 101 Patients.
    J Urol. 2018;199:325.
    PubMed     Text format    


  302. SUN M, Cole AP, Hanna N, Mucci LA, et al
    Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
    J Urol. 2018 Feb 1. pii: S0022-5347(18)30109-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    January 2018
  303. LOPCI E, Saita A, Lazzeri M, Lughezzani G, et al
    (68)Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI: a prospective observational study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30172-1. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  304. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Long-term outcome of a single intervention Population based Prostate Cancer Screening Study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30173-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  305. PRENDEVILLE S, Gertner M, Maganti M, Pintilie M, et al
    Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30175-7. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  306. LEE JS, Lee HS, Ha JS, Han KS, et al
    Subcutaneous fat distribution is a prognostic biomarker for men with castration-resistant prostate cancer.
    J Urol. 2018 Jan 20. pii: S0022-5347(18)30106-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  307. CHALFIN HJ, Glavaris SA, Malihi PD, Sperger JM, et al
    Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms.
    J Urol. 2018 Jan 12. pii: S0022-5347(18)30065-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  308. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol. 2018 Jan 10. pii: S0022-5347(18)30014-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  309. NGUYEN DP, Vertosick EA, Sharma V, Corradi RB, et al
    Does subclassification of pathologically organ-confined (pT2) prostate cancer provide prognostic discrimination of outcomes after radical prostatectomy?
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  310. KAPLAN SA
    Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Urol. 2018;199:7-8.
    PubMed     Text format    


  311. TANEJA SS
    Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    J Urol. 2018;199:28.
    PubMed     Text format    


  312. TANEJA SS
    Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2018;199:26-28.
    PubMed     Text format    


  313. PENSON DF
    Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Urol. 2018;199:19-20.
    PubMed     Text format    


  314. CADEDDU JA
    Re: Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    J Urol. 2018;199:13-14.
    PubMed     Text format    


  315. SALAMI SS
    Editorial Comment.
    J Urol. 2018;199:104.
    PubMed     Text format    


  316. SONN G
    Editorial Comment.
    J Urol. 2018;199:104-105.
    PubMed     Text format    


  317. GHANI KR, Miller DC, Montie JE
    Editorial Comment.
    J Urol. 2018;199:96-97.
    PubMed     Text format    


  318. JOHNSON DC, Litwin MS
    Editorial Comment.
    J Urol. 2018;199:96.
    PubMed     Text format    


  319. PATEL NA, Kasabwala K, Hu JC
    Editorial Comment.
    J Urol. 2018;199:138-139.
    PubMed     Text format    


  320. NAHAR B, Parekh DJ
    Editorial Comment.
    J Urol. 2018;199:138.
    PubMed     Text format    


  321. BHINDI B
    Editorial Comment.
    J Urol. 2018;199:87-88.
    PubMed     Text format    


  322. KAPOOR DA
    A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.
    J Urol. 2018;199:37-39.
    PubMed     Text format    


  323. TETREAULT-LAFLAMME A, Crook J, Hamm J, Pickles T, et al
    Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    J Urol. 2018;199:120-125.
    PubMed     Text format     Abstract available


  324. LUDWIG WW, Feng Z, Trock BJ, Humphreys E, et al
    Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    J Urol. 2018;199:114-119.
    PubMed     Text format     Abstract available


    December 2017
  325. OROM H, Biddle C, Underwood W 3rd, Nelson CJ, et al
    Worse urinary, sexual, and bowel function cause emotional distress and vice versa in men treated for prostate cancer.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78180-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  326. BERNSTEIN AN, Shoag JE, Golan R, Halpern JA, et al
    Contemporary Incidence & Outcomes of Prostate Cancer Lymph Node Metastases.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78181-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  327. AGHAZADEH MA, Frankel J, Belanger M, McLaughlin T, et al
    NCCN Favorable Intermediate Risk Prostate Cancer Patients: Is Active Surveillance Appropriate?
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78182-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  328. LIU RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, et al
    Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78068-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  329. VASAVADA SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, et al
    Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78097-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  330. GEARMAN DJ, Morlacco A, Cheville JC, Rangel LJ, et al
    Comparison of Pathological and Oncologic Outcomes in "Favorable Risk" GS 3+4 and Low Risk GS6 Prostate Cancer: Considerations for Active Surveillance.
    J Urol. 2017 Dec 7. pii: S0022-5347(17)78036-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  331. ATALA A
    Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer.
    J Urol. 2017;198:1213.
    PubMed     Text format    


  332. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;198:1212-1214.
    PubMed     Text format    


  333. TANEJA SS
    Re: Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy.
    J Urol. 2017;198:1211.
    PubMed     Text format    


  334. TANEJA SS
    Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    J Urol. 2017;198:1210-1211.
    PubMed     Text format    


  335. TANEJA SS
    Re: Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Urol. 2017;198:1209-1210.
    PubMed     Text format    


  336. TANEJA SS
    Re: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    J Urol. 2017;198:1208-1211.
    PubMed     Text format    


  337. MOREY AF
    Re: Radiation-Induced Complex Anterior Urinary Fistulation for Prostate Cancer: A Retrospective Multicenter Study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS).
    J Urol. 2017;198:1201-1203.
    PubMed     Text format    


  338. PENSON DF
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:1200.
    PubMed     Text format    


  339. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78003-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    November 2017
  340. HASSAN O, Han M, Zhou A, Paulk A, et al
    Incidence of Extra-Prostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed as "not Cancer" and for Selection Criteria for Active Surv
    J Urol. 2017 Nov 15. pii: S0022-5347(17)77915-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  341. PISHGAR F, Ebrahimi H, Moghaddam SS, Fitzmaurice C, et al
    Global, Regional and National Burden of Prostate Cancer, 1990 - 2015: Results from the Global Burden of Disease Study 2015.
    J Urol. 2017 Nov 9. pii: S0022-5347(17)77883-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  342. TANEJA SS
    Re: Weight Change, Obesity and Risk of Prostate Cancer Progression among Men with Clinically Localized Prostate Cancer.
    J Urol. 2017;198:982.
    PubMed     Text format    


  343. TANEJA SS
    Re: Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer.
    J Urol. 2017;198:982-983.
    PubMed     Text format    


  344. TANEJA SS
    Re: Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with National Comprehensive Cancer Network Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    J Urol. 2017;198:981.
    PubMed     Text format    


  345. TANEJA SS
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:980-983.
    PubMed     Text format    


    October 2017
  346. HALPERN JA, Oromendia C, Shoag JE, Mittal S, et al
    Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  347. AUDENET F, Vertosick EA, Fine SW, Sjoberg DD, et al
    Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77714-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  348. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed     Text format    


  349. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed     Text format    


  350. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed     Text format    


  351. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed     Text format    


  352. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed     Text format    


  353. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed     Text format    


  354. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed     Text format    


  355. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed     Text format    


  356. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed     Text format    


  357. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed     Text format    


    September 2017
  358. HOUSTON KA, King J, Li J, Jemal A, et al
    Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate-Specific Antigen Screening by Socioeconomic Status and Regions in the US, 2004- 2013.
    J Urol. 2017 Sep 28. pii: S0022-5347(17)77650-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  359. HEILBRUN LK, Powell IJ
    Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. T
    J Urol. 2017 Sep 26. pii: S0022-5347(17)77419-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  360. TOSOIAN JJ, Carter HB
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  361. SANDA MG
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  362. XU X, Zhang X, Zhong Y, Saad F, et al
    Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77561-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  363. NGUYEN HG, Welty C, Lindquist K, Ngo V, et al
    Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  364. SHIOTA M, Fujimoto N, Takeuchi A, Kashiwagi E, et al
    The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen-deprivation therapy and prognosis in metastatic prostate cancer.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77562-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  365. NYAME YA, Grimberg DC, Greene DJ, Gupta K, et al
    Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77563-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  366. GARCIA-REYES K, Nguyen HG, Zagoria RJ, Shinohara K, et al
    Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score >/= 3+4) with TRUS-MRI fusion biopsy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77560-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  367. NEHRA A, Parker WP, Haloi R, Park SS, et al
    Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.
    J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  368. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  369. ATALA A
    Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes.
    J Urol. 2017;198:486.
    PubMed     Text format    


  370. ATALA A
    Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
    J Urol. 2017;198:485-487.
    PubMed     Text format    


  371. TANEJA SS
    Re: Videotaping of Surgical Procedures and Outcomes following Extraperitoneal Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer.
    J Urol. 2017;198:483-484.
    PubMed     Text format    


  372. SEFTEL AD
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:466-468.
    PubMed     Text format    


  373. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    August 2017
  374. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  375. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  376. SIEMENS DR, Klotz L, Heidenreich A, Chowdhury S, et al
    Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.
    J Urol. 2017 Aug 18. pii: S0022-5347(17)77377-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  377. GARCIA-BARRERAS S, Sanchez-Salas R, Sivaraman A, Barret E, et al
    Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes.
    J Urol. 2017 Aug 17. pii: S0022-5347(17)77373-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  378. SHRESTHA E, White JR, Yu SH, Kulac I, et al
    Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.
    J Urol. 2017 Aug 7. pii: S0022-5347(17)77253-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  379. DAI C, Ganesan V, Zabell J, Nyame YA, et al
    Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.
    J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  380. AUFFENBERG GB, Lane BR, Linsell S, Brachulis A, et al
    A Roadmap for improving the management of men with favorable-risk prostate cancer.
    J Urol. 2017 Aug 3. pii: S0022-5347(17)77250-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  381. ATALA A
    Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer.
    J Urol. 2017;198:259.
    PubMed     Text format    


  382. TANEJA SS
    Re: Change in Salvage Radiotherapy Management Based on Guidance with FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    J Urol. 2017;198:256-257.
    PubMed     Text format    


  383. TANEJA SS
    Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
    J Urol. 2017;198:255-257.
    PubMed     Text format    


    July 2017
  384. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  385. TAPLIN ME, Armstrong AJ, Lin P, Krivoshik A, et al
    Clinical Outcomes of Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77187-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  386. TAMMELA TL, Haggman M, Ladjevardi S, Taari K, et al
    An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77188-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  387. GORIN MA, Rowe SP, Patel HD, Vidal I, et al
    PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77186-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  388. CHANG E, Jones TA, Natarajan S, Sharma D, et al
    Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77144-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  389. YANG L, Kibel AS, Colditz GA, Pakpahan R, et al
    Caution with Use of the Expanded Prostate Cancer Index Composite-50 Urinary Bother Scale: How Voiding Dysfunction Modifies Its Performance.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77147-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  390. STROUP SP, Moreira DM, Chen Z, Howard L, et al
    Biopsy-Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis, and Mortality in a Cohort of Men with High-Risk Prostate Cancer.
    J Urol. 2017 Jul 11. pii: S0022-5347(17)77098-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  391. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed     Text format    


  392. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed     Text format    


  393. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed     Text format    


  394. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed     Text format    


  395. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed     Text format    


  396. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed     Text format    


  397. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed     Text format    


    June 2017
  398. BHINDI B, Karnes RJ, Rangel LJ, Mason RJ, et al
    Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    J Urol. 2017 Jun 29. pii: S0022-5347(17)77027-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  399. JONES TA, Chin J, Mcleod D, Barkin J, et al
    High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial.
    J Urol. 2017 Jun 23. pii: S0022-5347(17)76734-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  400. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  401. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  402. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  403. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed     Text format    


  404. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed     Text format    


  405. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed     Text format    


  406. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed     Text format    


  407. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed     Text format    


  408. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed     Text format    


  409. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed     Text format    


  410. DENIZE J, Nouhaud FX, Cornu JN, Pfister C, et al
    Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R.
    J Urol. 2017 Jun 1. pii: S0022-5347(17)59378-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    May 2017
  411. YAN W, Shang Z, Zhou Z
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 May 31. pii: S0022-5347(17)57834-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  412. TELOKEN PE, Li J, Woods CG, Cohen RJ, et al
    The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure.
    J Urol. 2017 May 26. pii: S0022-5347(17)74541-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  413. TOMBAL B, Cornel EB, Persad R, Stari A, et al
    Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    J Urol. 2017 May 25. pii: S0022-5347(17)74503-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  414. FELDMAN AS, Meyer CP, Sanchez A, Krasnova A, et al
    Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population-Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    J Urol. 2017 May 25. pii: S0022-5347(17)74504-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  415. LEE DJ, Mallin K, Graves AJ, Chang SS, et al
    Recent changes in prostate cancer screening practices and prostate cancer epidemiology.
    J Urol. 2017 May 25. pii: S0022-5347(17)74517-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  416. HENRY MA, Howard DH, Davies BJ, Filson CP, et al
    Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.
    J Urol. 2017 May 6. pii: S0022-5347(17)64683-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  417. SEFTEL AD
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1266.
    PubMed     Text format    


  418. TANEJA SS
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1265-1266.
    PubMed     Text format    


  419. TANEJA SS
    Re: Development and Validation of a 24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer: A Matched, Retrospective Analysis.
    J Urol. 2017;197:1264-1266.
    PubMed     Text format    


    April 2017
  420. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  421. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    March 2017
  422. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  423. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  424. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  425. LEBDAI S, Bigot P, Leroux PA, Berthelot LP, et al
    Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.
    J Urol. 2017 Mar 18. pii: S0022-5347(17)40346-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    February 2017
  426. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed     Text format    


    December 2016
  427. KAPLAN SA
    Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease.
    J Urol. 2016;196:1713-1714.
    PubMed     Text format    


    June 2016
  428. KAPLAN SA
    Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged Men.
    J Urol. 2016;195:1838.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: